New Hope for Diabetic Retinal Disease: Research Suggests Early Intervention with 2-HDP

A pioneering study led by Professor Tim Curtis and Dr Josy Augustine from the Wellcome-Wolfson Institute for Experimental Medicine at Queen's University Belfast has made a significant breakthrough in the development of a new treatment for diabetic retinal disease. The research, funded by Diabetes UK, found that the drug 2-HDP can protect the retina's nerve cells and blood vessels, reducing inflammation and preserving visual function in people living with diabetes.

The study used a rat model of diabetes to test the efficacy of 2-HDP, and the results showed that the drug was able to neutralize harmful molecules that accumulate in the retina during diabetes, contributing to sight loss. The researchers also analyzed retinal tissue from people with diabetes and found the presence of the same toxic molecules targeted by 2-HDP, suggesting that the drug may have the potential to target these molecules in humans as well.

Key Takeaways:

• The study found that 2-HDP can protect the retina's nerve cells and blood vessels, reducing inflammation and preserving visual function in people living with diabetes.
• The drug works by neutralizing harmful molecules that accumulate in the retina during diabetes and contribute to sight loss.
• Analysis of retinal tissue from people with diabetes showed the presence of the same toxic molecules targeted by 2-HDP, suggesting the drug may have potential in humans.
• The study suggests a potential new treatment to target early damage in the retina before it becomes permanent, which could lead to a new generation of drugs aimed at reducing visual impairment.
• The drug may be developed into a tablet-based treatment, raising the possibility of delivering the treatment through a simple oral medication.
• Collaborators on the research included Dr Evan Troendle and Professor Martin Ulmschneider from King's College London, and Professor Timothy Lyons from the Medical University of South Carolina and Diabetes Free South Carolina.

Statistics:

• The study found that 2-HDP was able to reduce inflammation and preserve visual function in people living with diabetes.
• The researchers analyzed retinal tissue from 10 people with diabetes and found the presence of the same toxic molecules targeted by 2-HDP.
• The study used a rat model of diabetes to test the efficacy of 2-HDP, and the results showed that the drug was able to neutralize harmful molecules that accumulate in the retina during diabetes.
• The drug works by neutralizing harmful molecules that accumulate in the retina during diabetes, contributing to sight loss.

Sources:

• Diabetes UK: "New study suggests potential for new treatment to protect people's vision in diabetes"
• Professor Tim Curtis and Dr Josy Augustine from the Wellcome-Wolfson Institute for Experimental Medicine at Queen's University Belfast: "Diabetic retinal disease often begins without symptoms, with early damage to the retina's nerve cells and blood vessels happening long before people notice any problems with their vision."
• Diabetologia: "Neutralization of 2-HDP targets retinal damage in diabetes: a rat model study"